1. Scrip
  2. >>Business
  3. >>Deals

Gossamer Partners With Chiesi To Accelerate Seralutinib Development

Cash Will Fund Trial In Second, Larger Indication

 
• By Mandy Jackson

Already in Phase III for PAH, Gossamer said it can take seralutinib into Phase III for PH-ILD at least four years earlier than planned under its alliance with respiratory disease expert Chiesi.

Pulmonary hypertension is a cardiovascular condition characterized by high blood pressure in the pulmonary arteries 3D rendering
Topline Phase III data in PAH are expected in Q4 2025 • Source: Shutterstock

Gossamer Bio, Inc. is testing its inhaled kinase inhibitor seralutinib in a Phase III clinical trial as a potential disease-modifying treatment for pulmonary arterial hypertension (PAH), but has its eyes on the larger, less crowded market of pulmonary hypertension associated with interstitial lung disease (PH-ILD). Now, after signing a deal with Chiesi Farmaceutici S.p.A., Gossamer has the resources to begin a Phase III trial in PH-ILD at least four years sooner than planned.

Key Takeaways

  • Gossamer, down to its last drug candidate, sees a path to blockbuster status with seralutinib and can expand from PAH into a second indication of PH-ILD faster with new partner Chiesi.

  • The companies plan to start a Phase III study in PH-ILD in mid-2025, just ahead of a topline Phase III readout for the inhaled kinase inhibitor in PAH in the fourth quarter of 2025

San Diego-based Gossamer and the Italian respiratory and rare disease specialist Chiesi announced their global collaboration and license agreement on 6 May for the development and commercialization of seralutinib in PAH, PH-ILD and potentially other indications

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

 
• By Mandy Jackson

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.

Will Other Major MASH Deals Follow GSK/Boston Pharma?

 
• By Joseph Haas

GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.

AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics

 
• By Mandy Jackson

ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.

More from Business

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 
• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.